It was just, Whats new here? Raufman says
HRS-4729 (Jiangsu Hengrui / Kailera Therapeutics) - injectable peptide, Phase 1 initiated January 2025
Energy Production: By facilitating the transport of fatty acids into cells' mitochondria, L-Carnitine helps convert fats into energy, aiding in improved physical performance and endurance
This makes it a "dual-agonist." So, while it does the same job as a GLP-1 drug like semaglutide, it has an extra layer of action on the GIP pathway, which is what makes it unique
Soy protein-based formulas: recommendations for use in infant feeding
If youre switching from another GLP-1 program, your provider will review your current treatment and may continue therapy without restarting if medically appropriate